In prostate cancer the chemokines CXCL1 and CXCL2 have been implicated in promoting tumour associated bone disease by upregulating osteoclastogenesis, and in turn promoting tumour cell survival [10]. This evidence concerns the gene CXCL1 and neoplasm.